Akebia Therapeutics IncAKBA
Price$0.92

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $219.1M+36.8% YoYTTM through 30 Jun 2026
Net Income -$29.7MTTM through 30 Jun 2026
Free Cash Flow $40.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin77.0%
EBITDA Margin-6.2%
Operating Margin2.3%
Net Margin-13.5%

Returns

-33.1%ROE
-5.7%ROA

Balance Sheet Health

Debt / Equity7.14x
Current Ratio1.40x
Net Debt$32.8M
Cash & Equivalents$155.5M

Quality Metrics

Altman Z-Score-5.59
Piotroski F-Score6 / 9
FCF Margin18.4%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $236.2M
Diluted EPS-$0.11TTM
'19'20'21'22'23'24'25
FY2025: $-0.02

Dividend

No dividend

Capital Allocation

R&D Spend$70.5M
Capex Intensity0.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.